High dose transdermal nicotine for fast metabolizers of nicotine: A proof of concept placebo-controlled trial

Nicotine and Tobacco Research

Volumn 15, Issue 2, 2013, Pages 348-354

  Schnoll, Robert A ^a   Wileyto, E Paul ^a   Leone, Frank T ^b   Tyndale, Rachel F ^c   Benowitz, Neal L ^d,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; CARBON MONOXIDE; NICOTINE; PLACEBO;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPIRED AIR; HUMAN; INFLUENZA; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SMOKING CESSATION;

ADMINISTRATION, CUTANEOUS; ADULT; COTININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; NICOTINE; PLACEBOS;

EID: 84872876731     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts129     Document Type: Article

References (21)

1. Dale, L. C., Hurt, R. D., Offord, K. P., Croghan, I. T., Hays, J. T., Gomez-Dahl, L., et al. (1995). High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. Journal of the American Medical Association, 274, 1353-1358. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8528039.
2. Dempsey, D., Tutka, P., Jacob, P., 3rd., Allen, F., Schoedel, K., et al. (2004). Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology & Therapeutics, 76, 64-72. doi:10.1016/j.clpt.2004.02.011.
3. Fagerström, K. O., Kunze, M., Schoberberger, R., Breslau, N., Hughes, J. R., Hurt, R. D., et al. (1996). Nicotine dependence versus smoking prevalence: Comparisons among countries and categories of smokers. Tobacco Control, 5, 52-56. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8795860.
4. Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., et al. (2008). Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Retrieved from http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
5. Fredrickson, P. A., Hurt, R. D., Lee, G. M., Wingender, L., Croghan, I. T., Lauger, G., et al. (1995). High dose transdermal nicotine therapy for heavy smokers: Safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berlin), 122, 215-222. Retrieved from http://www.ncbi.nlm.nih.ov/pubmed/8748390.
6. Hatsukami, D. K., Mooney, M., Murphy, S., LeSage, M., Babb, D., & Hecht, S. (2007). Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacology, Biochemistry & Behavior, 86, 132-139. doi:10.1016/j.pbb.2006. 12.017.
7. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K.-O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1932883.
8. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & Swan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine & Tobacco Research, 5, 13-25. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12745503.
9. Hughes, J. R., Lesmes, G. R., Hatsukami, D. K., Richmond, R. L., Lichtenstein, E., Jorenby, D. E., et al. (1999). Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine & Tobacco Research, 1, 169-174. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21652735.
10. Kalman, D., Kahler, C. W., Tirch, D., Kaschub, C., Penk, W., & Monti, P. M. (2004). Twelve-week outcomes from an investigation of high-dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence. Psychology of Addictive Behaviors, 18, 78-82. doi:10.1037/0893-164X.18.1.78.
11. Lea, R. A., Dickson, S., & Benowitz, N. L. (2006). Withinsubject variation of the salivary 3HC/COT ratio in regular daily smokers: Prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. Journal of Analytical Toxicology, 30, 386-389. Retrieved from http://www. ncbi. nlm. nih. gov/pubmed/16872570.
12. Mooney, M. E., Li, Z. Z., Murphy, S. E., Pentel, P. R., Le, C., & Hatsukami, D. K. (2008). Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer, Epidemiology, Biomarkers, and Prevention, 17, 1396-1400. doi:10.1158/1055-9965.
13. Lerman, C., Tyndale, R., Patterson, F., Wileyto, E. P., Shields, P. G., Pinto, A., et al. (2006). Nicotine metabolite ratio predicts effi-cacy of transdermal nicotine for smoking cessation. Clinical Pharmacology & Therapeutics, 79, 600-608. doi:10.1016/j.clpt. 2006.02.006.
14. Perkins, K. A., Lerman, C., Fonte, C. A., Mercincavage, M., Stitzer, M. L., Chengappa, K. N., et al. (2010). Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clinical Pharmacology & Therapeutics, 88, 109-114. doi:10.1038/clpt.2010.65.
15. Schnoll, R. A., Patterson, F., Wileyto, E. P., Tyndale, R. F., Benowitz, N., & Lerman, C. (2009). Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Clinical Pharmacology & Therapeutics, 92, 6-11. doi:10.1016/j.pbb.2008.10.016.
16. Schnoll, R. A., Patterson, F., Wileyto, E. P., Heitjan, D. F., Shields, A. E., Asch, D. A., et al. (2010). Efficacy of extended duration transdermal nicotine therapy: A randomized trial. Annals of Internal Medicine, 152, 144-151. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20124230.
17. Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59 (Suppl 20), 22-33. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9881538.
18. Stapleton, J., Russell, M., Feyerabend, C., Wiseman, S. M., Gustavsson, G., Sawe, U., et al. (1995). Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction, 90, 31-42. doi:10.1046/j.1360-0443.
19. Stead, L. R., Bullen, P., Mant, C., & Lancaster, T. (2008). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, (21), CD000146. doi:10.1002/14651858.
20. Strasser, A. A., Benowitz, N. L., Pinto, A. G., Tang, K. Z., Hecht, S. S., Carmella, S. G., et al. (2011). Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiology Biomarkers & Prevention, 20, 234-238. doi:10.1158/1055-9965.
21. West, R., Hajek, P., Nilsson, F., Foulds, J., May, S., & Meadows, A. (2001). Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berlin), 153, 225-230. doi:10.1007/s002130000577.